Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Enhertu for HER2-Low Breast Cancer

    Enhertu for HER2-Low Breast Cancer

    FromBreastcancer.org Podcast

    Start listeningView podcast show

    Enhertu for HER2-Low Breast Cancer

    FromBreastcancer.org Podcast

    ratings:
    Length:
    11 minutes
    Released:
    Jul 8, 2022
    Format:
    Podcast episode

    Description

    At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
    Listen to the podcast to hear Dr. Wojciechowski explain:

    what HER2-low breast cancer is

    how Enhertu works

    how the results of the DESTINY-Breast-04 study will change practice
    Released:
    Jul 8, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.